

DAFTAR PUSTAKA

- Agussamad, I. (2022). The Effect of Health Education on Reducing Blood Pressure of Hypertensive Patients at USU Hospital Medan in 2022. *Science Midwifery*, 3410-3414.
- Andayani, T. M. (2013). *Farmakoekonomi Prinsip dan Metodologi*. Yogyakarta: Bursa Ilmu.
- Arundel, C., Lam, P. H., Gill, G. S., Patel, S., Panj Rath, G., Faselis, C., . . . Ahmed, A. (2019). Systolic Blood Pressure and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. *Journal of the American College of Cardiology*, 3054-3063. doi:10.1016/j.jacc.2019.04.022
- Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., . . . Munther, P. (2018). Heart Disease and Stroke Statistics-2018 Update: A Report From The American Heart Association. *Circulation*, 137, 67-492. doi:<https://doi.org/10.1161/CIR.0000000000000558>
- Bhandari, B., Rodriguez, B. S., & Masood, W. (2023). *Ischemic Cardiomyopathy*. Florida: StatPearls.
- BPJS Kesehatan, & Dewan Jaminan Sosial Nasional. (2021). *Statistik JKN 2015-2019*. Jakarta: Penerbit Dewan Jaminan Sosial Nasional.
- BPJS Kesehatan, & Dewan Jaminan Sosial Nasional. (2022). *Statistik JKN 2016-2021*. Jakarta: Penerbit Dewan Jaminan Sosial Nasional.
- Braunwald, E. (2014). The War Against Heart Failure: The Lancet Lecture. *The Lancet*, 385, 812-824.
- Buggey, J., Mentz, R. J., DeVore, A. D., & Velazquez, E. J. (2015). Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and

Clinical Impact. *Journal of Cardiac Failure*, 21(9), 741-750.
doi:10.1016/j.cardfail.2015.07.008

Cautela, J., Tartiere, J., Cohen-Solal, A., Bellemain-Apax, A., Theron, A., Tibi, T., . . . Girerd, N. (2020). Management of Low Blood Pressure in Ambulatory Heart Failure with Reduced Ejection Fraction Patients. *European Journal of Heart Failure*, 1357-1365.

Evaluation, T. I. (2019). *Indonesia*. Retrieved from <https://www.healthdata.org/research-analysis/health-by-location/profiles/indonesia>

Gaziano, T. A., Fonarow, G. C., Claggett, B., Chan, W. W., Deschaseaux-Vionet, C., Turner, S. J., . . . Solomon, S. D. (2016). Cost-Effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients with Heart Failure and Reduced Ejection Fraction. *JAMA Cardiology*, 1(6), 666-672.
doi:10.1001/jamacardio.2016.1747

Hajouli, S., & Ludhwani, D. (2022). *Heart Failure and Ejection Fraction*. Florida: StatPearls.

Harigustian, Y., Dewi, A., & Khoiriyati, A. (2016). Gambaran Karakteristik Pasien Gagal Jantung Usia 45-65 Tahun di Rumah Sakit PKU Muhammadiyah Gamping Sleman. *Indonesian Journal of Nursing Practices*, 1(1), 55-60.

Harikatang, A. D., Rampengan, S. H., & Jim, E. L. (2016). Hubungan antara Jarak Tempuh Tes Jalan 6 Menit dan Fraksi Ejeksi pada Pasien Gagal Jantung Kronik terhadap Kejadian Kardiovaskular. *Jurnal e-Clinic*, 249-256.

Haydock, P. M., & Flett, A. S. (2022). Management of Heart Failure with Reduced Ejection Fraction. *Heart*, 1571-1579. doi:10.1136/heartjnl-2020-318811

Heart. (2024). *Understanding Blood Pressure Readings*. Retrieved from Heart: <https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings>

- Heidenreich, P. A., Bozkurt, B., Aguilar, D., Byun, J. J., Colvin, M. M., Deswal, A., . . . Yancy, C. W. (2022). 2022 AHA/ACC/HFS Guideline for The Management of Heart Failure. *Journal of The American College of Cardiology*, 263-421. doi:10.1016/j.jacc.2021.12.012
- Indonesia. (2009). *Undang-undang Nomor 44 tahun 2009 tentang Rumah Sakit*. Jakarta: Pemerintah Pusat.
- Kemenkes. (2021). *Keputusan Kementerian Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/4801/2021 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Gagal Jantung*. Jakarta: Kementerian Kesehatan RI.
- Kemenkes. (2021). *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/4634/2021 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hipertensi Dewasa*. Jakarta: Kementerian Kesehatan RI.
- Kemenkes. (2023). *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES2197/2023 tentang Formularium Nasional*. Jakarta: Kementerian Kesehatan RI.
- Kemenkes RI. (2013). *Pedoman Penerapan Kajian Farmakoekonomi*. Jakarta: Kementerian Kesehatan RI.
- Kemenkes RI. (2016). *Pedoman Teknis Analisis Farmakoekonomi di Fasilitas Kesehatan*. Jakarta: Kementerian Kesehatan RI.
- Kesehatan, B. P. (2018). *Riset Kesehatan Dasar (RISKESDAS) 2018*. Jakarta: Kementerian Kesehatan RI.
- Khoiriyah, S. D., & Lestari, K. (2018). Review Artikel: Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia. *Farmaka*, 134-145.
- Levy, P., Lechat, P., Leizorovicz, A., & Levy, E. (1998). A Cost-Minimization of Heart Failure Therapy with Bisoprolol in The French Setting: An Analysis

from CIBIS Trial Data. *Cardiovascular Drugs and Therapy*, 301-305.
doi:10.1023/a:1007773901631

Lwanga, S., & Lemeshow, S. (1991). *Sample Size Determination in Health Studies: A Practical Manual*. England: World Health Organization.

Mazza, A., Townsend, D. M., Torin, G., Schiavon, L., Camerotto, A., Rigatelli, G., . . . Rubello, D. (2020). The Role of Sacubitril/valsartan in The Treatment of Chronic Heart Failure with Reduced Ejection Fraction in Hypertensive Patients with Comorbidities: From Clinical Trials to Real-world Settings. *Biomedicine & Pharmacotherapy*, 1-10.
doi:10.1016/j.biopha.2020.110596

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Bohm, M., . . . Skibellund, A. K. (2021). 2021 ESC Guidelines for The Diagnosis and Treatment of Acute and Chronic Heart Failure. *European Heart Journal*, 3599-3726. doi:10.1093/eurheartj/ehab368

McMurray, J. J., Trueman, D., Hancock, E., Cowie, M. R., Briggs, A., Taylor, M., . . . Deschaseaux, C. (2018). Cost-Effectiveness of Sacubitril/Valsartan in The Treatment of Heart Failure with Reduced Ejection Fraction. *Heart*, 104(12), 1006-1013. doi:10.1136/heartjnl-2016-310661

Menteri Kesehatan, R. (2016). *Peraturan Menteri Kesehatan RI Nomor 25 Tahun 2016 tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019*. Jakarta: Kementerian Kesehatan Republik Indonesia.

Merliana, H., & Sjaaf, A. C. (2017). Analisis Minimisasi Biaya Amlodipin Generik dan Bermerk pada Pengobatan Hipertensi di RS X Pekanbaru Tahun 2015. *Jurnal Ekonomi Kesehatan Indonesia*, 114-119.

Messerli, F. H., Rimoldi, S. F., & Bangalore, S. (2017). The Transition from Hypertension to Heart Failure: Contemporary Update. *JACC: Heart Failure*, 5(8), 543-551. doi:10.1016/j.jchf.2017.04.012

- Nicholls, M. G., & Richards, A. M. (2007). Disease Monitoring of Patients with Chronic Heart Failure. *Heart*, 519-523. doi:10.1136/2Fhrt.2005.078519
- Oh, G. C., & Cho, H.-J. (2020). Blood Pressure and Heart Failure. *Clinical Hypertension*, 1-8. doi:10.1186/s40885-019-0132-x
- PERKI. (2015). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hipertensi Dewasa*. Jakarta: Kementerian Kesehatan RI.
- PERKI. (2020). *Pedoman Tatalaksana Gagal Jantung*. Jakarta: Perhimpunan Dokter Kardiovaskular Indonesia.
- PERKI. (2023). *Pedoman Tatalaksana Gagal Jantung*. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Pinho-Gomes, A. C., & Rahimi, K. (2019). Management of Blood Pressure in Heart Failure. *Heart*, 589-595. doi:10.1136/heartjnl-2018-314438
- Prakasa, R. A., Valentina, D. C., Abdiana, R., Handayani, R., & BP, N. I. (2020). Analisis Faktor Risiko Pasien Gagal Jantung dengan Reduced Ejection Fraction di RSUD Dr. H. Abdul Moeloek Provinsi Lampung. *Jurnal Harian Regional*, 18(1), 22-26.
- Pudiarifanti, N., Pramantara, I. D., & Ikawati, Z. (2015). Faktor-faktor yang Mempengaruhi Kualitas Hidup Pasien Gagal Jantung Kronik. *Jurnal Manajemen dan Pelayanan Farmasi*, 259-266. doi:10.22146/jmpf.218
- Qomara, W. F., & Zakiyah, N. (2022). Review Artikel: Efektivitas Terapi Penambahan Ivabradine untuk Pasien Gagal Jantung dengan Penurunan Fraksi Ejeksi (Heart Failure Reduced Fraction Ejection). *Farmaka*, 47-58.
- Rahmawati, C., & Nurwahyuni, A. (2017). Analisis Minimalisasi Biaya Obat Antihipertensi antara Kombinasi Ramipril-Spironolakton dengan Valsartan pada Pasien Gagal Jantung Kongestif di Rumah Sakit Pemerintah XY di Jakarta Tahun 2014. *Jurnal Ekonomi Kesehatan Indonesia*, 191-200.

- Rashid, A. M., Khan, M. S., Fudim, M., DeWald, T. A., DeVore, A., & Butler, J. (2023). Management of Heart Failure with Reduced Ejection Fraction. *Current Problems in Cardiology*, 48. doi:10.1016/j.cpcardiol.2023.101596
- Reyes, E. B., Ha, J.-W., Firdaus, I., Ghazi, A. M., Phrommintikul, A., Sim, D., . . . Cowie, M. R. (2016). Heart Failure Across Asia: Same Healthcare Burden but Differences in Organization of Care. *International Journal of Cardiology*, 163-167. doi: doi.org/10.1016/j.ijcard.2016.07.256
- Robinson, R. S. (2014). Purposive Sampling. *Encyclopedia of Quality of Life and Well-Being Research*, 5243-5245.
- RSA UGM. (2021). *Panduan Praktik Klinis Penyakit Gagal Jantung Kronik*. Yogyakarta: RSA UGM.
- Scaria, S., Raju, R., Joseph, S., Mohan, A., & Nair, A. A. (2015). Pharmacoeconomics: Principles, Methods, and Indian Scenario. *Intenational Journal of Pharmaceutical Sciences Review and Research*, 37-46.
- Schwinger, R. H. (2021). Pathophysiology of Heart Failure. *Cardiovascular Diagnosis & Therapy*, 11, 263-276. doi:10.21037/cdt-20-302
- Siswanto, Susila, & Suyanto. (2015). *Metodologi Penelitian Kesehatan dan Kedokteran*. Yogyakarta: Bursa Ilmu.
- Slivnick, J., & Lampert, B. C. (2019). Hypertension and Heart Failure. *Heart Failure Clinics*, 531-541. doi:10.1016/j.hfc.2019.06.007
- Solomon, S. D., McMurray, J. J., Anand, I. S., Ge, J., Lam, C. S., Maggioni, A. P., . . . Lefkowitz, M. P. (2019). Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *The New England Journal of Medicine*, 381(17), 1609-1620. doi:10.1056/NEJMoa1908655
- Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandes-Llimos, F. (2021). Principles of Pharmacoeconomic Analysis: The Case of

- Pharmacist-Ied Interventions. *Pharmacy Practice*, 19, 1-10.
doi:10.18549/PharmPract.2021.1.2302
- Trisna, Y. (2016). *Aplikasi Farmakoekonomi*. Retrieved from Ikatan Apoteker Indonesia: <https://iai.id/news/artikel/aplikasi-farmakoekonomi>
- Tromp, J., Ouwerkerk, W., Cleland, J. G., Angermann, C. E., Dahlstrom, U., Tiew-Hwa Teng, K., . . . Dickstein, K. (2021). Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure. *JACC: Heart Failure*, 9, 349-359. doi:10.1016/j.jchf.2020.12.015
- Turgeon, R. D., & Barry, A. R. (2020). Developments in Heart Failure with Reduced Ejection Fraction. *JAMA*, 342.
- Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., . . . Schutte, A. E. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*, 75(6), 1334-1357. doi:10.1161/HYPERTENSIONAHA.120.15026
- WebMD. (2023). *Diastole vs Systole: Know Your Blood Pressure Numbers*. Retrieved from WebMD: <https://www.webmd.com/hypertension-high-blood-pressure/diastolic-and-systolic-blood-pressure-know-your-numbers>
- WHO. (2019). *Hypertension*. Retrieved from World Health Organization: https://www.who.int/health-topics/hypertension#tab=tab_1
- WHO. (2019). *Indonesia*. Retrieved from <https://data.who.int/countries/360>
- World Health Organization. (2005). *Guidelines for Estimating The Economic Burden of Diarrhoeal Disease, with Focus on Assessing The Costs of Rotavirus Diarrhoea*. Geneva: World Health Organization.
- Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey Jr, D. E., Colvin, M. M., . . . Westlake, C. (2017). 2017 ACC/AHA/HFSA Focused Update of The 2013 ACCF/AHA Guideline for The Management of Heart Failure. *Circulation*, 137-161. doi:10.1161/CIR.0000000000000509

- Yandrapalli, S., Khan, M. H., Rochlani, Y., & Aronow, W. A. (2018). Sacubitril/valsartan in Cardiovascular Disease: Evidence to Date and Place in Therapy. *Therapeutic Advances in Cardiovascular Disease*, 217-231. doi:10.1177/1753944718784536
- Zakiah, N., Sinuraya, R. K., Kusuma, A. S., Suwantika, A. A., & Lestari, K. (2021). Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia. *ClinicoEconomics and Outcomes Research*, 863-872. doi:10.2147/CEOR.S322740